Close Get in the Ring
  • Global Final 2024
  • Competitions
    • Evonik & Beiersdorf: Sustainability Challenge
    • Global Startup Competition
  • Challenges
  • Discover
  • About
  • News
Menu Get in the Ring

Pancreatic cancer is reaching its end

Steve Jobs would still be alive. Same as maybe your loved ones. Costa Rican startup Speratum is working around the clock to make this reality. Being a celebrity in Costa Rica already, founder & CEO Christian travelled with us to Singapore to convince investors, corporates and fellow entrepreneurs that the end of the painful death because of pancreatic cancer is near.

The speratum solution 
Speratum developed a potential cure for one of the deadliest forms of cancers – pancreatic cancer. During his graduate program, Christian found a specific microRNA molecule that every person has in high levels in his cells. However, these molecules disappear in tumors. Over the last years, Speratum has been able to develop this exact microRNA molecule in the lab. By injecting this molecule in the body, the tumor cells stop growing and eventually even disappear. And that’s without the side effects that current cancer treatments like chemotherapy cause. This method has only been tested on animals for now, but Speratum will move into clinical trials on humans in the next year.

IMG_2647 2

What’s making this happen?
After winning Get in the Ring Costa Rica, Christian travelled well-prepared to Singapore for the Global Conference. The original goal was to go home with the world title. But the Conference surprised him by creating value in unexpected areas. Through the Matchup sessions for example, where Christian had speed dates with different corporates and investment funds.

“Through the Matchup sessions, I was able to connect through UBS with a person who manages a $400 million oncology fund. I directly had a meeting with him, so from that perspective that was great!”

But new opportunities often also came from directions you
wouldn’t expect:

“A Singaporean company heard about us through Get in the Ring and reached out. They are also working with the same microRNA molecules as we are. However, they are focusing on cancer diagnostics, where we are using the technology for the treatment of cancer. Together we’re now working on a collaboration towards a full package, from the early diagnostics to the treatment of cancer. These are the sort of collaborations we are looking for and this specific one came directly as a result of Get in the Ring.”

It’s in the near future. But first…
Besides collaborations with companies on the other side of the world, Speratum has his eyes on taking the next step for his research, starting the clinical trials in humans. Together with Casper van Eijk, surgeon in pancreatic oncology and doctor of Steve Jobs in the final stages of his fight against cancer, Speratum will start its clinical trials in humans within the next year. However, before moving to Rotterdam (the Netherlands), Speratum is looking to raise capital in order to complete the final two experiments before the clinical trials in humans can start. For this they are looking for an investment of $2M at a $25M valuation. “Once we have the money, it will take us around 6 months until we can begin working with humans and start saving lives”.

  • About
    • About Get in the Ring
    • Contact
    • News
  • Participate
    • Competition
    • Challenges
    • FAQ

© Get in the Ring 2020 privacy policy and General Terms and Condition

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalit...
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT